Maria Dorobanțu *, Elisabeta Bădilă *, Cristina Deatcu *, Florentina Mehic *, Elena Pripoaie *
* Prof. dr. Maria Dorobanțu, Dr. Elisabeta Bădilă, Dr. Cristina Deatcu, Dr. Florentina Mehic, Dr.
Elena Pripoaie – Spitalul Clinic de Urgență Floreasca București
Abstract
Moxonidine has been developed as a centrally active antihypertensive drug with a distinctive mode of action that may offer advantages over existing therapies. The effect results from reduction in sympathetic nervous tone via actions at the 11 imidazoline receptors. Through its metabolic neutral profile, moxonidine is useful 1n mild-to moderate essential hypertension associated with metabolic disorders (obesity/diabetes mellitus), because it is effective and well tolerated.